Ann: Orthocell commences nerve repair study, page-6

An insider, the founder of SurgCenter, essentially a vast day hospital network in the US, has just bought 10,000,000 shares in MSB.

Now I apologise to those who hate MSB discussions to OCC, but there is relevance.

Someone like SurgCenter could very easily be interested in OCC's applications. They are a company that has "performed over 4100 Total Joint Replacements, more than any other outpatient surgery center in the United States". As a massive outpatient and short term stay hospital network with orthopedic specialisation, if they are looking at MSB, they will not be unaware of OCC's ATI treatment, Remplir or CelGro's tendon application.

MSB is a very riskier investment to me than OCC. OCC's treatment and products are far more easily encompassed in their existing treatment schedules. Its arguably a better fit.....both in investment and business terms.

US big Pharma is starting to sniff around orthopedic technologies, as I and Veritas have pointed out recently.....